Bretylium tosylate |
| Catalog No.GC30874 |
A class III antiarrhythmic agent
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 61-75-6
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Bretylium (tosylate) is an inhibitor of the presynaptic release of vasoconstrictor neurotransmitters. It is the sympathetic nerve and adrenergic ganglion blocking agent .(1) Bretylium tosylate inhibits adrenergic function presynaptically only after an initial release in neurotransmitter substance.(2) The reference for administration dose is 15 mg/kg (I.P).
[1]. McGinn R et al. Adenosine receptor inhibition attenuates the suppression of postexercise cutaneous blood flow. J Physiol. 2014 Jun 15;592(12):2667-78. [2]. Tew GA et al. Aging and aerobic fitness affect the contribution of noradrenergic sympathetic nerves to the rapid cutaneous vasodilator response to local heating. J Appl Physiol (1985). 2011 May;110(5):1264-70 [3]. Cakir B et al.Leptin inhibits gastric emptying in rats: role of CCK receptors and vagal afferent fibers. Physiol Res. 2007;56(3):315-22. Epub 2006 Jun 22.
| Cas No. | 61-75-6 | SDF | |
| Canonical SMILES | C[N+](C)(CC)CC1=CC=CC=C1Br.O=S(C2=CC=C(C)C=C2)([O-])=O | ||
| Formula | C18H24BrNO3S | M.Wt | 414.36 |
| Solubility | DMSO : ≥ 30 mg/mL (72.40 mM) | Storage | Store at -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 2.4134 mL | 12.0668 mL | 24.1336 mL |
| 5 mM | 0.4827 mL | 2.4134 mL | 4.8267 mL |
| 10 mM | 0.2413 mL | 1.2067 mL | 2.4134 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 7 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *